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LDL delivers cholesterol to lysosomes by receptor-
mediated endocytosis. Exit of cholesterol from lyso-
somes requires two proteins, membrane-bound Nie-
mann-Pick C1 (NPC1) and soluble NPC2. NPC2binds
cholesterol with its isooctyl side chain buried and its
3b-hydroxyl exposed. Here, we describe high-reso-
lution structures of the N-terminal domain (NTD) of
NPC1 and complexes with cholesterol and 25-hy-
droxycholesterol. NPC1(NTD) binds cholesterol in
an orientation opposite to NPC2: 3b-hydroxyl buried
and isooctyl side chain exposed. Cholesterol transfer
from NPC2 to NPC1(NTD) requires reorientation of
a helical subdomain in NPC1(NTD), enlarging the
opening for cholesterol entry. NPC1 with point muta-
tions in this subdomain (distinct from the binding
subdomain) cannot accept cholesterol from NPC2
and cannot restore cholesterol exit from lysosomes
in NPC1-deficient cells.We propose aworkingmodel
wherein after lysosomal hydrolysis of LDL-choles-
teryl esters, cholesterol binds NPC2, which transfers
it to NPC1(NTD), reversing its orientation and allow-
ing insertion of its isooctyl side chain into the outer
lysosomal membranes.
INTRODUCTION
Over the last 30 years, much has been learned about the
receptor-mediated endocytosis of plasma low-density lipopro-
tein (LDL) in coated pits and its subsequent delivery to endo-
somes and lysosomes (Brown and Goldstein, 1986; Roth,
2006). Each LDL particle contains 500 molecules of free
cholesterol and 1500 molecules of esterified cholesterol that
are hydrolyzed by acid lipase in the lumen of the lysosome (Gold-
stein et al., 1975). The liberated cholesterol must then exit the
lysosomal compartment in order to reach the plasma membraneand the endoplasmic reticulum (ER) where it performs structural
and regulatory roles, respectively (Demel and De Kruyff, 1976;
Simons and Ikonen, 2000; Goldstein et al., 2006). A major unan-
swered question is how this exit process is accomplished.
Insight into two proteins required for cholesterol exit from
lysosomes comes from Niemann-Pick Type C (NPC) disease
(Pentchev et al., 1995), a fatal hereditary disorder characterized
by the accumulation of cholesterol, sphingomyelin, and other
lipids in endosomes and lysosomes. Evidence indicates that
the primary cause is a failure of LDL-derived cholesterol to exit
the lysosomes, which secondarily causes the buildup of other
lipids. Mutations in either of two genes underlie NPC disease.
Both genes encode lysosomal cholesterol-binding proteins.
One gene encodes NPC1, a large 1278-amino acid polytopic
membrane protein that is localized to the limiting membranes
of endosomes and lysosomes (Carstea et al., 1997; Davies and
Ioannou, 2000). The other gene encodes NPC2, a small soluble
protein of 132 amino acids that resides in endosomes and lyso-
somes and is also secreted from the cell (Naureckiene et al.,
2000). Homozygous mutations in either gene produce the
same pattern of lysosomal lipid accumulation and the same clin-
ical phenotype, providing strong genetic evidence that both
proteins are required for cholesterol egress (Sleat et al., 2004).
NPC2 was shown previously to bind with high affinity to
cholesterol but not to cholesterol derivatives with hydrophilic
substitutions on the isooctyl side chain, such as 25-hydroxycho-
lesterol (25-HC) and 27-HC (Okamura et al., 1999; Friedland
et al., 2003; Ko et al., 2003; Infante et al., 2008b). Xu et al.
(2007) used X-ray crystallography to reveal the structure of
bovine NPC2 in complex with cholesterol sulfate, which contains
a sulfate in place of the 3b-hydroxyl group. Their data explained
why hydrophilic substitutions on the isooctyl side chain prevent
binding (Infante et al., 2008b). When cholesterol binds to NPC2,
its isooctyl side chain is buried deep within a hydrophobic
pocket. In contrast, the 3b-hydroxyl group is exposed on the
surface. This exposure explains why a sulfate substitution (as
in cholesterol sulfate) or a reversal of the orientation of the
hydroxyl from 3b to 3a (as in epicholesterol) does not prevent
binding. On the other hand, hydrophilic additions to the sideCell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc. 1213
chain, as in 25-HC, prevent burial of the side chain in the deep
hydrophobic pocket.
NPC1 is much more complex than NPC2, and no high-resolu-
tion structural information is available. NPC1 contains 13 pre-
dicted membrane-spanning helices and 3 large luminal domains
(Davies and Ioannou, 2000). The first luminal domain is desig-
nated the N-terminal domain (NTD). It consists of 240 amino
acids, which project into the lumen. This domain is hereafter
designated NPC1(NTD). The other two large luminal domains
are loops that span between transmembrane helices 2/3 and
8/9. We previously showed that full-length NPC1 binds
[3H]cholesterol with nanomolar affinity (Infante et al., 2008a).
Surprisingly, the binding site is localized to the soluble NTD
(Infante et al., 2008b). In sharp contrast to NPC2, NPC1(NTD)
binds not only cholesterol but also its oxygenated derivatives,
25-HC and 27-HC. On the other hand, NPC1(NTD) does not
bind sterols, such as cholesterol sulfate or epicholesterol, with
modifications at the 3b-hydroxyl position. These data led to the
suggestion that NPC1(NTD) binds cholesterol in an orientation
opposite to that of NPC2 with the 3b-hydroxyl of cholesterol
facing the interior of NPC1(NTD) and the isooctyl side chain
exposed (Infante et al., 2008b).
In a subsequent study, we provided evidence that cholesterol
could transfer between purified NPC1(NTD) and NPC2 in a bidi-
rectional fashion (Infante et al., 2008c).When [3H]cholesterol was
bound to NPC1(NTD) at 4C, the dissociation rate into deter-
gents was extremely slow, but the [3H]cholesterol transferred
rapidly to NPC2. The transfer could also proceed in the opposite
direction: NPC2 transferred its bound [3H]cholesterol to
NPC1(NTD) two orders of magnitude faster than when
[3H]cholesterol was delivered to NPC1(NTD) in detergent solu-
tion (Infante et al., 2008c). NPC2 can deliver bound cholesterol
directly to liposomes even in the absence of NPC1 (Cheruku
et al., 2006; Babalola et al., 2007; Xu et al., 2008; Infante et al.,
2008c). However, NPC1(NTD) could not deliver its bound choles-
terol to liposomes unless NPC2 was present as an intermediate
carrier. Although these studies showed a unique ability of NPC2
to facilitate entry and exit of cholesterol from NPC1(NTD), they
did not indicate which direction this transfer took within lyso-
somes, i.e., LDL to NPC2 to NPC1 versus LDL to NPC1 to
NPC2. Although the NPC2-to-NPC1 model seems more logical
(Infante et al., 2008c; Subramanian and Balch, 2008; Schulze
et al., 2009), direct data in support of this model are lacking.
In the current studies, we used X-ray crystallography to deter-
mine a high-resolution structure of NPC1(NTD) in the apoprotein
(apo) form and in complex with cholesterol or 25-HC. The protein
contains a deep pocket that surrounds the sterol, burying the 3b-
hydroxyl group and the tetracyclic ring but leaving the isooctyl
side chain partially exposed. This orientation is opposite to the
orientation of cholesterol bound to NPC2 in which the side chain
is buried and the 3b-hydroxyl exposed. Throughmutational anal-
ysis, we identified two functional subdomains of NPC1(NTD)—
one for sterol binding and the other for NPC2-mediated transfer.
We use these data to advance a hypothetical working model for
cholesterol transfer in which soluble NPC2 accepts cholesterol
from LDL and carries it to the membrane-bound N-terminal
domain of NPC1, which then inserts the cholesterol into the lyso-
somal membrane.1214 Cell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc.RESULTS
Crystal Structure of NPC1(NTD)
For structural studies, human NPC1(NTD) was produced in Hi-5
insect cells using a baculovirus vector. The soluble secreted
protein was purified from the culture medium. Initial attempts
at crystallization were hampered by heterogeneity attributable
to the five potential N-linked glycosylation sites (four of which
are conserved in various species) and a proline-rich C-terminal
region. After carrying out a systematic screen of mutations of
these four conserved glycosylation sites in combination with
C-terminal deletions, we obtained crystals from a construct
that spanned residues 23–252 and harbored three mutations
(N70Q, N122Q, N185Q) that removed three of the four conserved
glycosylation sites. When assayed for its binding to [3H]choles-
terol and [3H]25-HC, this protein exhibited binding kinetics
similar to that of wild-type (WT) NPC1(NTD) produced in CHO-
K1 cells (data not shown). Crystals were grown in the absence
and presence of cholesterol or 25-HC (Figure 1A). The structure
of NPC1(NTD) was determined by single wavelength anomalous
dispersion (SAD) phasing (Table 1) and refined to 1.8 A˚ (apopro-
tein and cholesterol complex) and 1.6 A˚ (25-HC complex).
NPC1(NTD) is composed of eight a helices that are flanked by
a three-strand mixed b sheet (Figure 1B). NPC1(NTD) contains
18 cysteine residues, all of which form disulfide bonds (C25-
C74, C31-C42, C63-C109, C75-C113, C97-C238, C100-C160,
C177-C184, C227-C243, C240-C247). Electron density is
present for two N-acetyl glucosamine molecules attached to
Asn222 (Figure S1B available online), and they form hydrogen
bonds with Glu110 and the carbonyl oxygen of Gly65 (Fig-
ure S1C). Electron density for an N-acetyl glucosamine is also
present at a previously unanticipated site, Asn158 (sequence,
NAC) (Figure S1A).
A comparison of the apoprotein (Figure 2A) and the sterol-
bound forms (Figures 2B and 2C) reveals virtually no change in
the structure of the protein upon sterol binding with a root-
mean-square deviation (rmsd) of 0.1 and 0.2 A˚ (apo versus
cholesterol and 25-HC, respectively) across all Ca atoms
(Figure S2). For the three structures, electron density is visible
for residues 23–247. Cholesterol and 25-HC are both clearly
visible, but cholesterol is less well ordered than 25-HC (see
B-factors in Table 1).
In the apo structure, the sterol-binding pocket is occupied by
two glycerol molecules and three water molecules (Figure 2A).
The glycerol in the apo structure likely results from diffusion
into the crystal during cryoprotection, as glycerol was not
present during protein purification or crystallization. In the
absence of sterols, the sterol-binding pocket is likely lined with
water molecules. At each end of the sterol-binding pocket are
openings toward solvent. One opening, located near the 3b-
hydroxyl group of the sterol, is just large enough for a single
water molecule to enter or exit (Figure 1C). We designate this
region as the water opening (W-opening). The other opening,
located at the end of the isooctyl side chain of the sterol mole-
cule, is slightly larger but not large enough to permit passage
of the tetracyclic ring without a conformational change (Figures
1C and 2D). We designate this region as the sterol opening
(S-opening). Cholesterol and 25-HC bind in a similar manner.
The 25-hydroxyl group on 25-HC does not form a specific inter-
action with the protein, instead forming a water-mediated inter-
action with the main chain carbonyl of Leu175 (Figure 3B).
Monomeric State of Soluble NPC1(NTD)
Based on size exclusion chromatography, soluble NPC1(NTD)
was hypothesized to exist as a dimer (Infante et al., 2008b).
Previous results with glycosylated proteins have shown anoma-
lous migration behavior on size exclusion chromatography
(Andrews, 1965). We used analytical ultracentrifugation sedi-
mentation velocity (SV) analysis to determine the oligomerization
state of NPC1(NTD) in solution. SV analysis of NPC1(NTD)
produced in CHO-K1 cells with all six of the predicted or identi-
fied glycosylation sites intact showed a single species of 3.2 S
Figure 1. Structure of NPC1(NTD) Bound to 25-
Hydroxycholesterol
(A) Stick models of cholesterol (left) and 25-HC (right) with
carbon positions numbered. Carbon and oxygen atoms are
colored green and red, respectively.
(B) NPC1(NTD) is represented as a ribbon diagram in gray, and
the disulfide bonds are shown in yellow. The positions of
cholesterol and 25-HC are essentially identical. For simplicity,
we show only the 25-HC molecule (colored in green). Helix3,
helix7, and helix8 are colored orange.
(C) The surface of NPC1(NTD), colored in gray, reveals open-
ings at either end of the bound sterol. The W-opening would
allow passage of a single water molecule (red spheres) but
not a sterol molecule. The S-opening would become large
enough to allow entry or exit of a sterol if the opening were
expanded slightly (see Figure 2D).
corresponding to a molecular mass of 41.9 kDa
(35% carbohydrate content by mass) (Figure S3).
SV analysis of the protein produced in insect cells,
with three of the glycosylation sites mutated,
showed a single species of 2.2 S corresponding
to a molecular mass of 30.3 kDa (15% carbohy-
drate content by mass) (Figure S3). Both results
are consistent with NPC1(NTD) being a monomer
in solution. Similar results were obtained from sedi-
mentation equilibrium analysis (data not shown).
Sterol-Binding Pocket
Thesterol-bindingpocketofNPC1(NTD) is linedpre-
dominately with hydrophobic residues (Figure 3A),
including Trp27, Leu83, Phe108, Pro202, Phe203,
and Ile205, consistent with the hydrophobicity of
cholesterol. The exceptions lie at the site of the
3b-hydroxyl group. Two polar residues, Asn41 and
Gln79, form direct hydrogen bonds with the 3b-
hydroxyl group (Figure 3B). In addition, Glu30 forms
a water-mediated interaction with the 3b-hydroxyl,
helping to stabilize binding of sterols and imposing
stereospecificity. The residues in this region would
not permit binding of the 3a-epimer of cholesterol
(epicholesterol) or bulky additions at this position
(Figure S4). These structural findings are consistent
with our previous binding data showing that NPC1
(NTD) does not bind epicholesterol or cholesterol sulfate (Infante
et al., 2008b).
The binding pocket of NPC1(NTD) tightly encloses the four
rings of the sterol. The pocket narrows around the C20 and C22
positions of the isooctyl side chain (Figure 2D) and begins to
expand and open toward solvent after C23. The binding pocket
is wider prior to C20, accommodating the larger size of the sterol
tetracyclic ring. Our previous binding data showed that hydroxyl
substitutions on the tetracyclic ring or on C20 diminish binding,
whilemodifications onC24, C25, andC27 permit binding (Infante
et al., 2008a, 2008b). These data are consistent with the size and
shape of the binding pocket. The size and shape of the binding
pocket restrict the entry and exit of sterols from NPC1(NTD)
and would require expansion of the S-opening. DisplacementCell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc. 1215
of helix3, helix7, helix8, and/or the loop between helix8/strand7
would allow sterols to bind or dissociate (Figure 1B, orange).
Alanine Scan Mutagenesis to Identify Residues
of NPC1(NTD) Required for Sterol Binding
To determine key residues in NPC1(NTD) that are important for
sterol binding, we performed an alanine scan mutagenesis
across the protein (amino acids 23–264) and assayed each
mutant for binding to [3H]cholesterol and [3H]25-HC (Figure S5).
We generated a panel of 84 mutant plasmids in which one, two,
or three contiguous amino acids were changed to alanines. This
panel included all 242 residues in NPC1(NTD) except for the
following: 4 conserved residues previously shown to have
normal binding activity when replaced with alanine (Asn103,
Gln117, Phe120, Tyr157) (Infante et al., 2008b); 1 conserved
residue that when mutated to alanine showed reduced choles-
terol binding (60% of normal) and virtually no 25-HC binding
(Gln79) (Infante et al., 2008b); 6 naturally occurring mutations
that were shown previously to have normal binding activity
(Gln92, Thr137, Pro166, Asn222, Asp242, Gly248) (Infante
et al., 2008b); 18 cysteines; and the C-terminal 32 residues
(amino acids 233–264), which when deleted do not decrease
binding of [3H]cholesterol or [3H]25-HC (data not shown).
As described in Supplemental Experimental Procedures, we
developed a rapid assay that allowed measurement of 3H-sterol
Table 1. DataCollectionandRefinementStatistics forNPC1(NTD)
25-HC Cholesterol Apo SeMethionine
Data Collection
Space group P64 P64 P64 P64
Cell dimensions (A˚)
a,b 65.926 65.691 66.181 65.441
c 82.988 82.367 82.644 82.672
Wavelength (A˚) 0.97940 0.97940 0.97940 0.97915
Resolution (A˚)
(final shell)
50–1.60
(1.63–1.60)
50.0–1.80
(1.83–1.80)
50–1.80
(1.83–1.80)
50–2.00
(2.03–2.00)
Reflections
Total 113183 87312 85984 69646
Unique 26443 18504 18538 13189
Completeness
(%)
97.8 (88.3) 98.8 (94.0) 98.1 (98.2) 96.3 (78.0)
Rsym (%) 3.1 5.9 8.0 7.6
Refinement
Rcryst (%) 17.5 17.4 18.0
Rfree (%) 20.3 20.7 22.1
rmsd
Bond
length (A˚)
0.012 0.012 0.012
Bond
angle ()
1.476 1.477 1.374
Bave
Protein (A˚2) 26.1 36.7 35.7
Ligand (A˚2) 22.9 43.6 54.61216 Cell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc.binding to aliquots of concentrated media from CHO-K1 cells
that had been transfected with plasmids encoding epitope-
tagged WT or mutant versions of NPC1(NTD). The amount of
secreted protein was determined by immunoblotting with an
antibody directed against the FLAG epitope tag. Of the 84
mutants, 5 did not produce secreted protein (Y28-E30, L80/
Q81, W189/I190, M193/F194, and V208/F209). Binding assays
were performed by trapping the His-tagged proteins with bound
3H-sterol on nickel columns as described in Supplemental
Experimental Procedures. Media from cells transfected with
mock vector showed no binding of [3H]cholesterol or [3H]25-
HC (<20 fmol/tube), whereas media from cells transfected with
WT NPC1(NTD) showed 860–1500 fmol/tube and 780–1000
fmol/tube for [3H]cholesterol and [3H]25-HC, respectively
(Figure S5B). Six of the 84 NPC1(NTD) mutant proteins showed
binding that was less than 25% of WT (Figure S5B, blue). All of
these mutations (R39-N41, T82/L83, N106-F108, D197/N198,
P202/F203, and T204/I205) replaced residues that mapped to
the binding pocket (Figure 4, blue). These residues include the
majority of the hydrophobic amino acids that line the binding
pocket around the tetracyclic ring, except for Trp27, whose
replacement reduced [3H]cholesterol binding to a level slightly
above the 25% threshold (Figure S5B). Of the two hydrophilic
residues that form direct hydrogen bonds with the 3b-hydroxy
group (Figure 3B), the replacement of Asn41 with alanine disrup-
ted [3H]cholesterol binding by 90% (Figure S5B). The other
hydrophilic residue (Gln79) was previously shown to produce
a 40% reduction in cholesterol binding when replaced with
alanine (Infante et al., 2008b). The only amino acid in the
sterol-binding domain that could not be evaluated in the alanine
scan was Glu30, which forms a water-mediated bond with the
3b-hydroxyl. This mutant protein was not secreted into the
media. We identified seven mutant NPC1(NTD) proteins that ex-
hibited a preferential reduction of binding of [3H]25-HC as
compared with [3H]cholesterol (Figure S5B, pink). All seven of
these mutations replaced amino acids that mapped either to
the binding pocket (V26/W27 and G199/Q200) or to adjacent
amino acids (F101/Y102, L144/Q145, Y146/Y147, T187/N188,
and N195/K196) (Figure S7, pink).
To validate the major findings from the assays with unfractio-
nated culturemedia, we purified themutant protein with the least
amount of cholesterol binding (P202A/F203A) and analyzed it in
detail. Asshown inFigures5Aand5B, thepurifiedprotein showed
no detectable binding of either [3H]cholesterol or [3H]25-HC.
Alanine Scan Mutagenesis to Identify Residues
Required for NPC2-Mediated Transfer
Previously, we showed that NPC2 catalyzes the bidirectional
transfer of cholesterol between NPC1(NTD) and liposomes
in vitro (Infante et al., 2008c). To test the amino acids in
NPC1(NTD) that are important for this action, we performed
a transfer assay with all of the alanine scan mutants except for
the eight mutants whose [3H]cholesterol-binding activity was
less than 50% of the WT. For this assay, we prepared stable
complexes of [3H]cholesterol:NPC1(NTD) and purified them by
immunoaffinity chromatography as described in Supplemental
Experimental Procedures. We then measured the transfer of
the bound [3H]cholesterol to liposomes in the presence and
absence of purified NPC2. In the absence of NPC2, less than
8% of bound [3H]cholesterol from WT NPC1(NTD) was trans-
ferred to liposomes. In the presence of NPC2, WT NPC1(NTD)
transferred an additional 54%–90% of bound [3H]cholesterol in
three experiments (Figure S6B, shaded region) with an average
of 80%. Six mutant NPC1(NTD) proteins transferred less than
25% of their bound [3H]cholesterol to liposomes in an NPC2-
dependent manner (Figures 4 and S6B, red). These mutations
replaced residues L175/L176, D180/D182, N185, T187/N188,
E191/Y192, and G199/Q200, all of which map to a surface of
a subdomain of NPC1(NTD) spanning amino acids 162–200.
Figure 2. Sterol-Binding Pocket
(A–C) The sigmaA-weighted 2Fo-Fc electron density
map contoured at 1s within the sterol-binding pocket
is shown in gray mesh for the apoNPC1(NTD) (A), the
cholesterol-bound (B), and 25-HC-bound (C) forms.
The binding pocket is essentially identical in
apoNPC1(NTD) and the sterol-bound forms. The
binding pocket of apoNPC1(NTD) is occupied by two
glycerol and three water molecules. NPC1(NTD) is
colored gray, bound ligands are colored green, and
water molecules are shown as red spheres.
(D) The internal surface of the binding pocket is shown
in gray. Bound 25-HC is shown in green.
Figure 3. Expanded View of Sterol-Binding
Pocket
(A) Residues that line the binding pocket are
shown in yellow, and the sterol molecule is shown
in green.
(B) Hydrogen bonds between residues of
NPC1(NTD) and the hydroxyl groups of the sterol
are denoted by gray dots. Residues involved in
hydrogen bonds are colored yellow, and the sterol
molecule is colored green. Nitrogen atoms are
shown in blue, and oxygen atoms are shown in
red. Water molecules are shown as red spheres.
This region includes helices 7 and 8 and
the intervening loop (Figure 4, red). Of the
six mutants in this region, the two most defi-
cient in transfer are L175A/L176A and
E191A/Y192A. Two of these four WT resi-
dues (L176 and Y192) are identical in 12 out
of 12 mammalian species, and the other
two (L175 and E191) are identical in 11 of
the 12 species (Infante et al., 2008b).
To validate the findings from the above
transfer assays done with culture media, we
purified one of the mutants, L175A/L176A,
that showed a marked decrease in the amount of NPC2-depen-
dent [3H]cholesterol transfer from NPC1(NTD) to liposomes.
When incubated with [3H]cholesterol for 24 hr at 4C, a time
necessary to achieve equilibrium binding in the absence of
NPC2 (Infante et al., 2008c), themutant protein boundcholesterol
with similar affinity to that of the WT protein (Figure 5C). More-
over, its rates of association and dissociation of [3H]cholesterol
at 4C and 37C were virtually identical to those of WT
NPC1(NTD) (Figure S8). Equilibrium binding for both WT and
mutant proteins was achieved within 30 min at 37C, and disso-
ciation of previously bound [3H]cholesterol for both proteins
occurred rapidly at 37C and extremely slowly at 4C (Figure S8).Cell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc. 1217
Despite its normal binding kinetics, themutant protein showed
a marked defect in NPC2-stimulated transfer of cholesterol to
liposomes (Figure 5E). As compared to WT NPC1(NTD), the
mutant protein required five times more NPC2 to transfer an
equivalent amount of [3H]cholesterol to liposomes. To show
that this transfer defect is the result of defective interaction
with NPC2 and not with liposomes, we tested the ability of
NPC2 to transfer its cholesterol to WT NPC1(NTD) and to this
mutant. Within 15 min, NPC2 transferred 4-fold more [3H]choles-
terol toWTNPC1(NTD) as compared to the L175A/L176Amutant
(Figure 5D).
CholesterolBindingandTransferMutantsFail toRestore
Function to NPC1-Deficient Cells
To assay the function ofmutant NPC1 proteins, wemeasured the
two reactions that occur when cholesterol or oxysterols reach
the ER: (1) activation of acyl-CoA:cholesterol acyltransferase
(ACAT), thereby increasing incorporation of radiolabeled fatty
acids into cholesteryl esters (Pentchev et al., 1995; Liscum and
Faust, 1987); and (2) inhibition of the proteolytic processing of
sterol regulatory element-binding proteins (SREBPs), thereby
inactivating transcription of genes for cholesterol synthesis
and uptake (Brown and Goldstein, 1997; Infante et al., 2008a).
Figure 4. Location of Functionally Impor-
tant Residues in NPC1(NTD)
(A) Amino acid sequence of NPC1(NTD) with func-
tionally important residues highlighted. Blue ovals
denote residues that exhibit decreased binding of
cholesterol and 25-HC by >75% when mutated to
alanine. Red ovals denote residues that exhibit
decreased transfer of cholesterol to liposomes
by >70% when mutated to alanine. Cyan ovals
denote naturally occurring mutations in patients
with NPC1 disease. Residues that line the binding
pocket are shaded yellow. N-linked glycosylation
sites that were eliminated are shaded green. The
secondary structure of NPC1(NTD) is indicated
below the sequence.
(B and C) Ribbon diagram (B) and surface repre-
sentation (C) of NPC1(NTD), showing the positions
of functionally important residues. Bound 25-HC is
shown as a stick model in green. Color coding is
the same as in (A). The locations of the L175,
L176, P202, and F203 residues are denoted by
arrows.
Figure 5F shows an experiment in which
we transfected plasmids encoding full-
length WT and mutant NPC1 into CHO
4-4-19 cells. These cells lack NPC1 func-
tion as a result of a point mutation
(G660R) in transmembrane helix 3 (L. Lis-
cum, personal communication; Dahl
et al., 1992; Infante et al., 2008b). Forty-
eight hours after transfection, the cells
were incubated for 5 hr with varying
concentrations of b-VLDL, a cholesterol-
rich lipoprotein that binds LDL receptors
and delivers cholesterol to lysosomes.
(Because of its high affinity for the LDL receptor, b-VLDL is
frequently used as a ligand in cell culture studies; van Driel
et al., 1987.) After incubationwith b-VLDL, the cells then received
[14C]oleate and the incorporation into cholesteryl [14C]oleate was
measured. When transfected with a control (mock) plasmid, the
CHO 4-4-19 cells showed little cholesteryl [14C]oleate formation.
Expression of WT NPC1 allowed b-VLDL to stimulate cholesteryl
oleate formation by 20-fold (Figure 5F). Full-length NPC1
harboring the P202A/F203A mutation in the NTD was markedly
defective in restoring sensitivity to b-VLDL (Figure 5F, blue
triangles). Similar defects were seen when full-length NPC1 con-
tained the L175A/L176A mutation (red triangles). None of the
mutant proteins interfered with the ability of 25-HC to stimulate
cholesteryl ester formation, a response that is normal in the
NPC1 mutant cells (Figure 5G).
Immunoblotting revealed that the mutant proteins were ex-
pressed at the same level as WT (Figure 5F, inset). Both mutant
and WT proteins showed a diffuse band characteristic of fully
glycosylated lysosomal proteins that have left the ER (Watari
et al., 1999). Moreover, treatment of the mutant proteins with
the glycosidase Endo H (which removes only high mannose
chains) did not alter their migration pattern on SDS-PAGE,
providing further evidence that the mutant proteins had folded1218 Cell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc.
properly and left the ER (data not shown). In the same experi-
ment, Endo H treatment of a control protein containing a high
mannose chain (Site-1 protease) (DeBose-Boyd et al., 1999)
showed the expected increase in electrophoretic mobility.
To study the inhibition of SREBP processing, we employed
a standard protocol in which CHO 4-4-19 cells were deprived
of sterols and then incubated with b-VLDL for 5 hr after which
membrane and nuclear extracts were subjected to immunoblot-
ting to detect the full-length precursor and the processed nuclear
form of SREBP-2. Mock-transfected CHO 4-4-19 cells failed to
suppress SREBP-2 cleavage when incubated with b-VLDL
(Figure 5H, lanes 2 and 3). Suppression was restored by trans-
fection with a plasmid encoding WT NPC1 (lanes 4–7), but not
with plasmids encoding the binding-defective mutant (lanes
8–11) or transfer-defective mutant (lanes 12–15). None of these
plasmids affected suppression by 25-HC, which is normal in
NPC1-deficient cells (Figure 5I).
DISCUSSION
Considered together with previous studies of NPC1 and NPC2
(Xu et al., 2007; Infante et al., 2008a, 2008b, 2008c), the current
studies permit us to formulate a hypothetical working model to
explain the requirement for these two proteins in the egress of
lipoprotein-derived cholesterol from lysosomes (see Figure 6C).
The major consideration in formulating this model is the striking
reversal in the orientation of cholesterol when it transfers
between NPC2 and NPC1.
As described previously by Xu et al. (2007), cholesterol binds
to NPC2 with its 3b-hydroxyl group exposed to solvent
(Figure 6A). The exposure of the 3b-hydroxyl allows NPC2 to
bind lipoprotein-derived cholesterol either before or immediately
after the fatty acid on the hydroxyl group is removed by acid
lipase. Even though NPC2 can deliver cholesterol directly to lipo-
somes in vitro as mentioned in the Introduction, genetics reveals
that NPC2 alone is not sufficient for cholesterol egress from lyso-
somes, and hence the requirement for NPC1 (Pentchev, 2004;
Sleat et al., 2004). We hypothesize that the NPC1 requirement
may be imposed to overcome either of two impediments: (1)
cholesterol should enter the hydrophobic lysosomal membrane
most readily when its hydrophobic isooctyl side chain leads
the way; when cholesterol is bound to NPC2, the hydrophobic
side chain is deeply buried in the protein and it cannot lead the
way into the lysosomal membrane bilayer and/or (2) the carbohy-
drate glycocalyx that lines the interior of the lysosomal me-
mbrane (Neiss, 1984) creates a diffusion barrier that would
prevent NPC2 from interacting directly with the membrane (Kol-
ter and Sandhoff, 2005; Schulze et al., 2009). Both of these
impediments could be overcome if NPC2 transferred its choles-
terol to NPC1(NTD). This would reverse the orientation of choles-
terol so that its hydrophobic side chain could lead the way into
themembrane, and it likely provides amechanism for cholesterol
to transit the glycocalyx.
The model of Figure 6C is supported by our previously pub-
lished in vitro data showing that [3H]cholesterol binds to and
dissociates from NPC1(NTD) extremely slowly and that both
processes are accelerated in the presence of NPC2 (Infante
et al., 2008c). As is apparent from the NPC1(NTD) crystal struc-ture, entry or exit of cholesterol from NPC1(NTD) requires
enlargement of the S-opening, which could be accomplished
by displacement of the loop between helix8/strand7 and/or
a shift in the position of helix3, helix7, or helix8 (Figures 1B,
orange). Mutagenesis studies support the involvement of resi-
dues near the S-opening but not the W-opening in the NPC2-
facilitated transfer of cholesterol. Alanine substitutions at
multiple sites in helix7, helix8, and the helix8/strand7 loop
decreased the ability of NPC2 to open the NPC1(NTD)-binding
site as indicated by a reduced ability of NPC2 to facilitate the
transfer of NPC1(NTD)-bound [3H]cholesterol to liposomes
(Figures 4 and S6, red). This phenotype was not observed with
mutations in helix3 or any other site in the protein. These data
suggest that NPC2 interacts with NPC1(NTD) to elicit a rear-
rangement in helix7, helix8, and the intervening loop between
helix8/strand7, thereby expanding the S-opening and allowing
cholesterol to enter or exit from the binding pocket of
NPC1(NTD). Helix3 may also contribute to the expansion of the
S-opening. Comparison of the apo, cholesterol-bound, and
25-HC-bound structures shows that a slight displacement of
helix3 is possible with the largest shift (1 A˚) occurring at
Asn86/Leu87 (Figure S2). Exit through the S-opening is consis-
tent with the idea that the hydrophobic side chain of cholesterol
is the first part of the sterol to leave NPC1(NTD), thereby allowing
it to insert into the lysosomal membrane.
The cell culture data of Figure 5 support the notion that transfer
of cholesterol betweenNPC1andNPC2 is required for exit of lipo-
protein-derived cholesterol from lysosomes. When the L175A/
L176Amutationwas introduced into full-length NPC1, the protein
could not restore egress of cholesterol from lysosomes to
a normal degreeas judgedbya failure of normal cholesterol ester-
ification (Figure 5F) and suppression of SREBP-2 cleavage
(Figure 5H) in the presence of b-VLDL. These data provide strong
support for the notion that cholesterol must be transferred
between NPC2 and NPC1(NTD) in order to exit the lysosome.
However, the result does not in itself determine that the transfer
goes in the direction of NPC2-to-NPC1. In our model, this
directionality is hypothesized in order to overcome the two
impediments discussed above, i.e., the directionality of choles-
terol insertion into the bilayer and the necessity to transit the
glycocalyx.
The NTD is separated from the membrane domain of NPC1 by
a linker composed of 20 amino acids, 8 of which are prolines
(Figure 6D). It is likely that this sequence extends in such a way
that the NTD can project through the glycocalyx, which has
been measured at8 nm (Neiss, 1984). This glycocalyx is shown
as stipples in Figure 6C. In order to deliver cholesterol to the
membrane, the NTD would have to move toward the membrane.
Moreover, another protein would have to enlarge the S-opening
on NPC1(NTD) in order for cholesterol to leave the NTD and enter
themembrane. It is likely that theseprocessesaremediatedby the
membrane domain of NPC1, which contains 13 transmembrane
helices and two large loops that project into the lysosomal lumen.
Five of the 13 transmembrane helices (no. 3–7) bear sequence
homology to the sterol-sensing domains of Scap, a polytopic
membrane protein in the SREBP pathway that has been shown
to bind cholesterol with high affinity (Radhakrishnan et al., 2004).
It seems likely that thesterol-sensingdomainofNPC1participatesCell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc. 1219
Figure 5. Biochemical and Functional Analysis of Sterol Binding and Transfer Mutants
(A–C) 3H-Sterol binding. Each reaction, in a final volume of 80 ml buffer Cwith 0.004%NP-40, contained 220 ng purifiedWT or mutant NPC1(NTD)-LVPRGS-His8-
FLAG, 1 mg BSA, and indicated concentration of [3H]cholesterol (132 dpm/fmol) (A and C) or [3H]25-HC (165 dpm/fmol) (B). After incubation for 24 hr at 4C, the
amount of bound 3H-sterol was measured as described in Supplemental Experimental Procedures. Each value is the average of duplicate assays and represents
total binding after subtraction of a blank value (10–70 fmol/tube). Mean variation for each of the duplicate assays in (A), (B), and (C) was 6.1%, 5.0%, and 5.0%,
respectively.
(D) [3H]Cholesterol transfer from NPC2 to NPC1(NTD). Each reaction, in a final volume of 200 ml buffer D (pH 5.5) without detergent, contained40 pmol of donor
protein NPC2-FLAG complexed to [3H]cholesterol (830 fmol, 132 dpm/fmol) and increasing concentrations of purified WT or mutant NPC1(NTD)-LVPRGS-His8-
FLAG acceptor protein. After incubation for 15 min at 4C, the amount of [3H]cholesterol transferred to NPC1(NTD) was measured by Ni-NTA-agarose chroma-
tography as described in the [3H]cholesterol transfer assay in Experimental Procedures. Each value is the average of duplicate assays and represents percentage
of [3H]cholesterol transferred to NPC1(NTD). The 100% value for transfer from NPC2 was 830 fmol/tube. Mean variation for each of the duplicate assays for WT
and mutant was 7.9% and 8.2%, respectively.
(E) [3H]Cholesterol transfer from NPC1(NTD) to liposomes as a function of NPC2. Each reaction, in a final volume of 200 ml buffer D (pH 5.5) without detergent,
contained 50 pmol of WT or L175A/L176A versions of NPC1(NTD)-LVPRGS-His8-FLAG, each complexed to [3H]cholesterol (950 and 660 fmol, respectively;
132 dpm/fmol); 20 mg PC liposomes labeled with Texas red dye; and increasing concentrations of NPC2-His10. After incubation for 10 min at 4C, the amount of1220 Cell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc.
in cholesterol transfer. In Figure 6C, we show the NPC1(NTD)
interacting with the membrane domain of the same protein.
However, we have not ruled out the possibility that NPC1(NTD)
transfers the cholesterol directly to the membrane.
In transferring its bound cholesterol to the lysosomal
membrane, the NTD of NPC1 could interact either with its own
membrane domain (as shown in Figure 6C), in which case it
might transfer the cholesterol to the putative sterol-sensing
domain in transmembrane helices 3–7, or with the membrane
domain of a neighboring NPC1 molecule. In this regard, Ohgami
et al. (2004) reported that they could crosslink photoactivated
cholesterol to NPC1 when the photoactivated cholesterol was
added to the culture medium of WT CHO cells. The reaction
was reduced when the cells harbored mutant NPC1 with a point
mutation in transmembrane helix3, which is part of the sterol-
sensing domain. Once cholesterol is transferred to the me-
mbrane domain of NPC1, it could be flipped to the cytosolic
leaflet fromwhich it could then be picked up by cytosolic choles-
terol-binding proteins. It seems likely that additional proteins
would be required for the export process. Clues may come
from the study of patients who have the NPC disease phenotype
but do not have mutations in NPC1 or NPC2.
One caveat to the model of Figure 6C arises because we have
thus far been unable to demonstrate a stable complex between
NPC1(NTD) and NPC2. Therefore, the postulated interaction
between these two proteins might be transient. We are currently
exploring methods to capture such transient interactions using
NMR, chemical crosslinkers, and fluorescence energy transfer
methods.
Although the model of Figure 6 still remains to be proven, it
offers a scheme that can be tested by further experiments using
in vitro biochemistry and cell culture methodologies. It is hoped
that testing of this model may lead to new insights into a funda-
mental biologic process—namely, how lipoprotein-derived
cholesterol is transported out of the lysosomal compartment
so that it can exert its structural and regulatory functions within
the cell. Understanding this process hopefully will shed new light
on a devastating disease.EXPERIMENTAL PROCEDURES
Expression and Purification of NPC1(NTD) for Crystallization
Sf9 cells infected with His6-ENLYFQGA-NPC1(23–252)(N70Q/N122Q/N185Q)
baculovirus (Wasilko and Lee, 2006) were used to infect Hi-5 cells at 1 3 106
cells/ml in Excel-405 medium. After incubation for 96 hr at 27C, cells were
pelleted by centrifugation, and the medium was concentrated by tangential
flow filtration and exchanged into buffer A. The concentrated medium from
6 l of culture was applied to a 10 ml Ni-NTA column equilibrated in buffer A,
washed sequentially with buffer A containing 5mM and then 25mM imidazole,
and eluted with buffer A containing 250 mM imidazole. Fractions containing
NPC1(NTD) were pooled, concentrated, and buffer-exchanged into buffer B,
after which 0.9 mg/ml of His-tagged TEV protease was added, and themixture
was gently rocked overnight at 21C. Following removal of the His-tag from
His6-ENLYFQGA-NPC1(23–252)(N70Q/N122Q/N185Q), the mixture was ap-
plied to a 10 ml Ni-NTA column, and the flow-through was directly applied to
aMonoQ column equilibrated in buffer B. NPC1(NTD) was eluted using a linear
gradient from 50 to 500 mM NaCl, and fractions containing NPC1(NTD) were
pooled and concentrated. The concentrated NPC1(NTD) was then applied to
a Superdex 200 gel filtration column equilibrated with buffer containing
10 mM Tris-chloride (pH 7.5), 50 mM NaCl, and 0.01% NaN3. Fractions
containing NPC1(NTD) were pooled and concentrated to 30 mg/ml prior to
crystallization.
Selenomethionine-containing NPC1(NTD) was generated in TNi-pro cells
(Expression Systems) adapted to grow in ESF-921 methionine-free medium.
At 16 and 40 hr after baculoviral infection with His6-ENLYFQGA-NPC1(23–
252)(N70Q/N122Q/N185Q), the medium was supplemented with 100 mg/ml
L-selenomethionine. Selenomethionine-containing NPC1(NTD) was purified
as described above for the unlabeled protein.
Crystallization and Structure Determination
Prior to crystallization, cholesterol or 25-HC, at a final concentration of 1 mM
in 5% (v/v) ethanol, was incubated with NPC1(NTD) overnight at 4C. Initial
crystals were obtained using the Fluidigm TOPAZ system. Crystals of
apoNPC1(NTD) or the cholesterol-bound and 25-HC-bound forms were
produced bymixing protein at 30mg/ml with an equal volume of reservoir solu-
tion containing 25% (w/v) polyethylene glycol 1500, 100 mM MES acid, and
30 mM glycine at pH 3.25 (final pH, 4.0). Crystals were transferred stepwise
into reservoir solution containing 25% (v/v) glycerol and soaked overnight at
21C. Crystals were flash-frozen in a 160C nitrogen stream. The crystals
belong to space group P64. Diffraction data were collected at the Advanced
Photon Source (Argonne, IL, USA) beam line 19-ID and 19-BM and processed
with HKL2000 (Otwinowski andMinor, 1997) and theCCP4 suite (Collaborative[3H]cholesterol transferred to liposomes was measured in the flow-through of the nickel column as described for the [3H]cholesterol transfer assay in Experi-
mental Procedures. Each value is the average of duplicate assays and represents the percentage of [3H]cholesterol transferred to liposomes. Blank values in
the absence of NPC2 (5%–6% transfer) were subtracted. The 100% values for transfer from WT and L175A/176A versions of NPC1(NTD) were 950 and
660 fmol/tube, respectively. Mean variation for each of the duplicate assays for WT and mutant was 8.8% and 9.3%, respectively.
(F–I) Cholesterol esterification and SREBP-2 processing in mutant CHO cells lacking NPC1 function transfected with NPC1 cDNAs. Mutant CHO 4-4-19 cells
were set up for experiments and transfected with 2 mg pcDNA3.1 or withWT or mutant versions of pCMV-NPC1-His8-FLAG (F and G), or they were cotransfected
with 0.4 mg pcDNA3.1 or with WT or mutant versions of pTK-NPC1-His8-FLAG3 plus 3 mg pTK-HSV-BP2 (H and I) as described in Experimental Procedures.
Twenty-four hours after transfection, the medium was switched to medium A containing 5% newborn calf lipoprotein-deficient serum, 5 mM compactin, and
50 mM sodium mevalonate. After incubation for 24 hr, the medium was switched to the same medium containing 50 mM compactin and various concentrations
of b-VLDL (F and H) or 25-HC (G and I) as indicated.
(F and G) Cholesterol esterification. After incubation for 5 hr at 37C, each cell monolayer was pulse-labeled for 1 hr with 0.2 mM sodium [14C]oleate (6301 dpm/
pmol). The cells were then harvested for measurement of their content of cholesteryl [14C]oleate and [14C]triglycerides. Each value is the average of duplicate
incubations. Mean variation for each of the duplicate incubations for WT, P202A/F203A, and L175A/L176A was 9.6%, 14.5%, and 4.3%, respectively. The
rate of synthesis of [14C]triglycerides for mock, NPC1 WT, NPC1(P202A/F203A), and NPC1(L175A/L176A) transfected cells incubated with 5 mg/ml b-VLDL
was 340, 396, 352, and 365 nmol/hr per mg protein, respectively. The rate of synthesis of [14C]triglycerides incubated with 25-HC was 347, 496, 304, and
434 nmol/hr per mg protein, respectively.
(H and I) SREBP-2 processing. After incubation for 4 hr at 37C, cells received a direct addition of 25 mg/ml of N-acetyl-leucinal-leucinal norleucinal. After 1 hr,
triplicate dishes were harvested and pooled for preparation of nuclear extracts and 100,000 gmembrane fractions, which were analyzed by immunoblotting for
the indicated protein. The concentrations of antibodies were 0.2 and 4 mg/ml for SREBP-2 (anti-HSV) and NPC1 (anti-FLAG), respectively. All filters were exposed
on X-ray film for 2–10 s.
(A–I) Similar results were obtained in three or more independent experiments.Cell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc. 1221
Computation Project, 1994). Four selenium sites were found from SAD data
using ShelXD (Schneider and Sheldrick, 2002), and the resulting maps were
improved by density modification using DM (Cowtan, 1994). The model was
built with the program COOT (Emsley and Cowtan, 2004). Initial refinement
was performed with CNS (Brunger et al., 1998), and the final cycles of refine-
ment were performed with REFMAC (Winn et al., 2001). Figures were gener-
ated with PYMOL (http://www.pymol.org).
[3H]Cholesterol Transfer Assays for Purified NPC Proteins
The transfer assays, including methods for isolation of complexes of
[3H]cholesterol bound to NPC1(NTD) or NPC2 and for preparation of lipo-
somes, have been previously described (Infante et al., 2008c). For transfer
assays of NPC1(NTD) to liposomes, incubation conditions are described in
Figure 5E. After incubation, the 200 ml mixture was diluted with 750 ml of buffer
C and loaded onto a 2 ml column packed with 0.3 ml of Ni-NTA-agarose
beads pre-equilibrated with buffer C. Each column was washed with 1 ml of
buffer C. The amount of [3H]cholesterol transferred to liposomes was quanti-
fied by scintillation counting of the combined flow-through and wash fractions.
For transfer assays of NPC2 to NPC1(NTD), incubation conditions are
Figure 6. Model for Egress of Lipoprotein-Derived
Cholesterol from Lysosomes
(A) Structure of NPC2 bound to cholesterol. Redrawn from
Xu, et al. (2007).
(B) Structure of NPC1(NTD) bound to cholesterol.
(C) Proposed pathway for transfer of cholesterol from LDL
or b-VLDL to NPC2 to NPC1 to membranes. See Discus-
sion for explanation of this working model.
(D) Sequence of amino acids 247–266 that link the NTD to
the first transmembrane domain in NPC1 (Davies and
Ioannou, 2000). Prolines in this sequence are boxed.
These prolines are invariant in 12 vertebrate species
(Infante et al., 2008b) except for P256, which is conserved
in 8 of the 12 species.
described in Figure 5D. After incubation, each mixture
was processed as above except that the column was
washed with 3 ml of buffer C and eluted with 250 mM
imidazole, after which the eluate was subjected to scintil-
lation counting.
Assays for Cholesterol Esterification and SREBP-
2 Processing in Cultured Cells
Mutant CHO4-4-19 cells, defective in NPC1 function (Dahl
et al., 1992), were transfected and tested for incorporation
of [14C]oleate into cholesteryl [14C]oleate and proteolytic
processing of SREBP-2 as previously described (Infante
et al., 2008b). For assays of cholesterol esterification, cells
were transfected with 2 mg pcDNA3.1 or pCMV-NPC1-
His8-FLAG (wild-type or mutant versions). For assays
of SREBP-2 processing, cells were cotransfected with
0.5 mg pcDNA3.1 or pTK-NPC1-His8-FLAG3 (wild-type
or mutant versions) plus 3 mg pTK-HSV-BP2. Incubation
conditions are described in the legend to Figure 5.
ACCESSION NUMBERS
The atomic coordinateshavebeendeposited in theProtein
Data Bank with accession codes 3GKH (apoNPC1(NTD)),
3GKI (cholesterol-bound), and 3GKJ (25-HC-bound).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental
Procedures (Materials, Buffers and Medium, Plasmid
Constructions, Alanine Scan Mutagenesis, Purification of Epitope-Tagged
NPC1(NTD) and NPC2 from Medium of Transfected CHO Cells, 3H-Sterol
Binding Assays for Purified NPC1(NTD), and Analytical Ultracentrifugation),
eight figures, and Supplemental References and can be found with this article
online at http://www.cell.com/supplemental/S0092-8674(09)00393-6.
ACKNOWLEDGMENTS
We thank Dorothy Goddard, Lisa Henry, Bethany Cartwright, and Maya Palnit-
kar for excellent technical assistance; Lisa Beatty and Shomanike Head for
invaluable help with tissue culture; Dr. Chad Brautigam for help with analytical
ultracentrifugation; and Dr. Laura Liscum for the gift of CHO 4-4-19 cells. This
workwas supported by grants from theNational Institutes of Health (HL20948),
Welch Foundation (I-1185), andPerot Family Foundation. R.E.I. andM.L.W. are
supportedbyMedical Scientist TrainingProgramGrant 5T32 (GM08014). R.E.I.
is also supported by the Ara Parseghian Medical Research Foundation. J.D. is
an Investigator of theHowardHughesMedical Institute. Crystallographic struc-
tures were derived from work performed at Argonne National Laboratory,
Structural Biology Center at the Advanced Photon Source (operated by1222 Cell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc.
UChicagoArgonne, LLC, for theU.S.Department of Energy,OfficeofBiological
and Environmental Research under Contract DE-AC02-06CH11357).
Received: January 6, 2009
Revised: February 10, 2009
Accepted: March 23, 2009
Published: June 25, 2009
REFERENCES
Andrews, P. (1965). The gel-filtration behaviour of proteins related to their
molecular weights over a wide range. Biochem. J. 96, 595–606.
Babalola, J.O., Wendeler, M., Breiden, B., Arenz, C., Schwarzmann, G., Loca-
telli-Hoops, S., and Sandhoff, K. (2007). Development of an assay for the inter-
membrane transfer of cholesterol by Niemann-Pick C2 protein. Biol. Chem.
388, 617–626.
Brown, M.S., and Goldstein, J.L. (1986). A receptor-mediated pathway for
cholesterol homeostasis. Science 232, 34–47.
Brown, M.S., and Goldstein, J.L. (1997). The SREBP pathway: Regulation of
cholesterol metabolism by proteolysis of a membrane-bound transcription
factor. Cell 89, 331–340.
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-
Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al.
(1998). Crystallography & NMR system: A new software suite for macromolec-
ular structure determination. Acta Crystallogr. D Biol. Crystallogr. D54,
905–921.
Carstea, E.D., Morris, J.A., Coleman, K.G., Loftus, S.K., Zhang, D., Cummings,
C., Gu, J., Rosenfeld, M.A., Pavan,W.J., Krizman, D.B., et al. (1997). Niemann-
Pick C1 disease gene: Homology to mediators of cholesterol homeostasis.
Science 277, 228–231.
Cheruku, S.R., Xu, Z., Dutia, R., Lobel, P., and Storch, J. (2006). Mechanism of
cholesterol transfer from the Niemann-Pick type C2 protein to model
membranes supports a role in lysosomal cholesterol transport. J. Biol.
Chem. 281, 31594–31604.
Collaborative Computation Project, Number 4. (1994). The CCP4 suite:
Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr.
D50, 760–763.
Cowtan, K. (1994). Joint CCP4 and ESF-EACBM Newsletter on Protein Crys-
tallography 31, 34–38.
Dahl, N.K., Reed, K.L., Daunais, M.S., Faust, J.R., and Liscum, L. (1992). Isola-
tion and characterization of Chinese hamster ovary cells defective in the intra-
cellular metabolism of low density lipoprotein-derived cholesterol. J. Biol.
Chem. 267, 4889–4896.
Davies, J.P., and Ioannou, Y.A. (2000). Topological analysis of Niemann-Pick
C1 protein reveals that themembrane orientation of the putative sterol-sensing
domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and
sterol regulatory element binding protein cleavage-activating protein. J. Biol.
Chem. 275, 24367–24374.
DeBose-Boyd, R.A., Brown, M.S., Li, W.-P., Nohturfft, A., Goldstein, J.L., and
Espenshade, P.J. (1999). Transport-dependent proteolysis of SREBP: Reloca-
tion of Site-1 protease fromGolgi to ER obviates the need for SREBP transport
to Golgi. Cell 99, 703–712.
Demel, R.A., and De Kruyff, B. (1976). The function of sterols in membranes.
Biochim. Biophys. Acta 457, 109–132.
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular
graphics. Acta Crystallogr. D Biol. Crystallogr. D60, 2126–2132.
Friedland, N., Liou, H.-L., Lobel, P., and Stock, A.M. (2003). Structure of
a cholesterol-binding protein deficient in Niemann-Pick type C2 disease.
Proc. Natl. Acad. Sci. USA 100, 2512–2517.
Goldstein, J.L., Dana, S.E., Faust, J.R., Beaudet, A.L., and Brown,M.S. (1975).
Role of lysosomal acid lipase in the metabolism of plasma low density lipopro-
tein: Observations in cultured fibroblasts from a patient with cholesteryl ester
storage disease. J. Biol. Chem. 250, 8487–8495.Goldstein, J.L., DeBose-Boyd, R.A., and Brown, M.S. (2006). Protein sensors
for membrane sterols. Cell 124, 35–46.
Infante, R.E., Abi-Mosleh, L., Radhakrishnan, A., Dale, J.D., Brown, M.S., and
Goldstein, J.L. (2008a). Purified NPC1 protein: I. Binding of cholesterol and
oxysterols to a 1278-amino acid membrane protein. J. Biol. Chem. 283,
1052–1063.
Infante, R.E., Radhakrishnan, A., Abi-Mosleh, L., Kinch, L.N., Wang, M.L.,
Grishin, N.V., Goldstein, J.L., and Brown, M.S. (2008b). Purified NPC1 protein:
II. Localization of sterol binding to a 240-amino acid soluble luminal loop.
J. Biol. Chem. 283, 1064–1075.
Infante, R.E., Wang, M.L., Radhakrishnan, A., Kwon, H.J., Brown, M.S., and
Goldstein, J.L. (2008c). NPC2 facilitates bidirectional transfer of cholesterol
between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes.
Proc. Natl. Acad. Sci. USA 105, 15287–15292.
Ko, D.C., Binkley, J., Sidow, A., and Scott, M.P. (2003). The integrity of
a cholesterol-binding pocket in Niemann-Pick C2 protein is necessary to
control lysosome cholesterol levels. Proc. Natl. Acad. Sci. USA 100, 2518–
2525.
Kolter, T., and Sandhoff, K. (2005). Principles of lysosomal membrane
digestion: stimulation of sphingolipid degradation by sphingo-lipid activator
proteins and anionic lysosomal lipids. Annu. Rev. Cell Dev. Biol. 21, 81–103.
Liscum, L., and Faust, J.R. (1987). Low density lipoprotein (LDL)-mediated
suppression of cholesterol synthesis and LDL uptake is defective in Nie-
mann-Pick type C fibroblasts. J. Biol. Chem. 262, 17002–17008.
Naureckiene, S., Sleat, D.E., Lackland, H., Fensom, A., Vanier, M.T., Wattiaux,
R., Jadot, M., and Lobel, P. (2000). Identification of HE1 as the second gene of
Niemann-Pick C disease. Science 290, 2298–2301.
Neiss, W.F. (1984). A coat of glycoconjugates on the inner surface of the lyso-
somal membrane in the rat kidney. Histochemistry 80, 603–608.
Ohgami, N., Ko, D.C., Thomas, M., Scott, M.P., Chang, C.C.Y., and Chang, T.-
Y. (2004). Binding between the Niemann-Pick C1 protein and a photoactivat-
able cholesterol analog requires a functional sterol-sensing domain. Proc.
Natl. Acad. Sci. USA 101, 12473–12478.
Okamura, N., Kiuchi, S., Tamba, M., Kashima, T., Hiramoto, S., Baba, T.,
Dacheux, F., Dacheux, J.-L., Sugita, Y., and Jin, Y.-Z. (1999). A porcine
homolog of the major secretory protein of human epididymis, HE1, specifically
binds cholesterol. Biochim. Biophys. Acta 1438, 377–387.
Otwinowski, Z., and Minor, W. (1997). Processing of x-ray diffraction data
collected in oscillation mode. Methods Enzymol. 276, 307–326.
Pentchev, P.G. (2004). Niemann-Pick C research from mouse to gene. Bio-
chim. Biophys. Acta 1685, 3–7.
Pentchev, P.G., Vanier, M.T., Suzuki, K., and Patterson, M.C. (1995). Niemann-
Pick disease type C: A cellular cholesterol lipidosis. In The Metabolic and
Molecular Basis of Inherited Disease, C.R. Scriver, A.L. Beaudet, W.S. Sly,
and D. Valle, eds. (New York: McGraw-Hill Inc.), pp. 2625–2639.
Radhakrishnan, A., Sun, L.-P., Kwon, H.J., Brown, M.S., and Goldstein, J.L.
(2004). Direct binding of cholesterol to the purified membrane region of
SCAP: mechanism for a sterol-sensing domain. Mol. Cell 15, 259–268.
Roth, M.G. (2006). Clathrin-mediated endocytosis before fluorescent proteins.
Nat. Rev. Mol. Cell Biol. 7, 63–68.
Schneider, T.R., and Sheldrick, G.M. (2002). Substructure solution with
SHELXD. Acta Crystallogr. D Biol. Crystallogr. D58, 1772–1779.
Schulze, H., Kolter, T., and Sandhoff, K. (2009). Principles of lysosomal
membrane degradation. Cellular topology and biochemistry of lysosomal lipid
degradation. Biochim. Biophys. Acta 1793, 674–683.
Simons, K., and Ikonen, E. (2000). How cells handle cholesterol. Science 290,
1721–1726.
Sleat, D.E., Wiseman, J.A., El-Banna, M., Price, S.M., Verot, L., Shen, M.M.,
Tint, G.S., Vanier, M.T., Walkley, S.U., and Lobel, P. (2004). Genetic evidence
for nonredundant functional cooperativity between NPC1 and NPC2 in lipid
transport. Proc. Natl. Acad. Sci. USA 101, 5886–5891.Cell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc. 1223
Subramanian, K., and Balch, W.E. (2008). NPC1/NPC2 function as a tag team
duo to mobilize cholesterol. Proc. Natl. Acad. Sci. USA 105, 15223–15224.
van Driel, I.R., Goldstein, J.L., Su¨dhof, T.C., and Brown, M.S. (1987). First
cysteine-rich repeat in ligand-binding domain of low density lipoprotein
receptor binds Ca2+ and monoclonal antibodies, but not lipoproteins. J. Biol.
Chem. 262, 17443–17449.
Wasilko, D.J., and Lee, S.E. (2006). TIPS: Titerless infected-cells preservation
and scale-up. Bioprocessing J. 5, 29–32.
Watari, H., Blanchette-Mackie, E.J., Dwyer, N.K., Glick, J.M., Patel, S., Neu-
feld, E.B., Brady, R.O., Pentchev, P.G., and Strauss, J.F., III. (1999). Nie-1224 Cell 137, 1213–1224, June 26, 2009 ª2009 Elsevier Inc.mann-Pick C1 protein: Obligatory roles for N-terminal domains and lysosomal
targeting in cholesterol mobilization. Proc. Natl. Acad. Sci. USA 96, 805–810.
Winn,M.D., Isupov,M.N., andMurshudov, G.N. (2001). Use of TLS parameters
tomodel anisotropic displacements in macromolecular refinement. Acta Crys-
tallogr. D Biol. Crystallogr. D57, 122–133.
Xu, S., Benoff, B., Liou, H.-L., Lobel, P., and Stock, A.M. (2007). Structural
basis of sterol binding by NPC2, a lysosomal protein deficient in Niemann-
Pick type C2 disease. J. Biol. Chem. 282, 23525–23531.
Xu, Z., Farver, W., Kodukula, S., and Storch, J. (2008). Regulation of sterol
transplant between membranes and NPC2. Biochemistry 47, 11134–11143.
